Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib in First-line Advanced NSCLC With KRAS G12C Mutation
NCT04933695Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jan 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of sotorasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoint: Objective Response Rate up to 30.9 months. Started Jan 2022; status: terminated.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04933695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933695.